Investor Presentaiton

Strong track record Unique model Large moat Significant opportunity Compounding growth Industry leading exposure to blockbuster products 8 Top 15 biopharma (median) 1.5x 12 TYSABRI PROMACTA farxiga Sales of $1-3bn (1) Tremfya CABOMETYX® Erleada Myozyme Cimzia Xtandi Entyvio Sales >$3bn (1) trikafta imbruvicá ROYALTY PHARMA Portfolio includes premier products and franchises backed by strong support from marketers ROYALTY PHARMA (1) Calculated based on 2021 end market sales and excludes products tied to recently expired royalties. 19

View entire presentation